SCHEMBL16701049

SCHEMBL16701049

COc1ccc(CN(Cc2ccccc2)Cc2ccc(OC)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.67
▸ TSHR P16473 3/20 0.61
▸ MAPK1 P28482 2/20 0.61
▸ ACHE P22303 1/20 0.58
▸ G6PC1 P35575 1/20 0.56
▸ SIGMAR1 Q99720 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.54
▸ CNR2 P34972 1/20 0.53
▸ CALM1 P0DP23 1/20 0.53
▸ CAMKK2 Q96RR4 1/20 0.53
▸ TAS2R14 Q9NYV8 1/20 0.53
▸ CA4 P22748 1/20 0.52
▸ APLNR P35414 1/20 0.52
▸ HTT P42858 1/20 0.51
▸ OPRM1 P35372 1/20 0.51
▸ OPRL1 P41146 1/20 0.51
▸ NPC1 O15118 1/20 0.50
▸ POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28778941 1.00 LTA4H (0.67) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL5270803 0.91 APLNR (0.59) LTA4HTSHRMAPK1ACHEAPLNR
SCHEMBL12049800 0.91 APLNR (0.59) LTA4HTSHRMAPK1ACHEAPLNR
SCHEMBL16706897 0.91 LTA4H (0.56) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL22340700 0.90 TSHR (0.75) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL18938857 0.87 ALDH1A1 (0.59) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL16039094 0.86 ACHE (0.76) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL10039134 0.86 CALM1 (0.73) LTA4HTSHRMAPK1ACHEG6PC1
SCHEMBL13658163 0.85 MAOB (0.57) LTA4HAPLNRHTT
SCHEMBL12128183 0.83 BCHE (0.62) LTA4HTSHRMAPK1ACHENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861568-B1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIV OSLO (NO) 2019-04-17 — — EP disclosed
EP-2861568-B1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIV OSLO (NO) 2019-04-17 — — EP disclosed
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 — — US disclosed
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 — — US disclosed
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 — — US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 — — US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 — — US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 — — US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 — — US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 — — US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 — — US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 — — US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 — — US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 LTA4H 4198/4885TSHR 2005/4885MAPK1 1087/4885
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 LTA4H 4183/4885TSHR 2085/4885MAPK1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback